nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranylcypromine—CYP2A6—Methoxsalen—psoriasis	0.119	0.155	CbGbCtD
Tranylcypromine—CYP1A2—Clobetasol propionate—psoriasis	0.0868	0.113	CbGbCtD
Tranylcypromine—CYP2A6—Prednisolone—psoriasis	0.0581	0.0756	CbGbCtD
Tranylcypromine—CYP1A2—Methoxsalen—psoriasis	0.0456	0.0593	CbGbCtD
Tranylcypromine—CYP2D6—Hydroxyurea—psoriasis	0.0411	0.0535	CbGbCtD
Tranylcypromine—CYP2A6—Dexamethasone—psoriasis	0.0342	0.0446	CbGbCtD
Tranylcypromine—CYP2C19—Cholecalciferol—psoriasis	0.0327	0.0426	CbGbCtD
Tranylcypromine—CYP3A4—Calcitriol—psoriasis	0.0307	0.04	CbGbCtD
Tranylcypromine—CYP2C9—Cholecalciferol—psoriasis	0.0272	0.0354	CbGbCtD
Tranylcypromine—CYP2D6—Cholecalciferol—psoriasis	0.0249	0.0324	CbGbCtD
Tranylcypromine—CYP3A4—Methoxsalen—psoriasis	0.0239	0.0311	CbGbCtD
Tranylcypromine—CYP2C19—Prednisone—psoriasis	0.0227	0.0295	CbGbCtD
Tranylcypromine—CYP2E1—Dexamethasone—psoriasis	0.0226	0.0294	CbGbCtD
Tranylcypromine—CYP2C19—Cyclosporine—psoriasis	0.0215	0.028	CbGbCtD
Tranylcypromine—CYP2C9—Cyclosporine—psoriasis	0.0179	0.0233	CbGbCtD
Tranylcypromine—CYP2D6—Cyclosporine—psoriasis	0.0164	0.0213	CbGbCtD
Tranylcypromine—CYP3A4—Cholecalciferol—psoriasis	0.0158	0.0206	CbGbCtD
Tranylcypromine—CYP2C19—Dexamethasone—psoriasis	0.0142	0.0184	CbGbCtD
Tranylcypromine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0137	0.0179	CbGbCtD
Tranylcypromine—CYP3A4—Triamcinolone—psoriasis	0.0137	0.0179	CbGbCtD
Tranylcypromine—CYP2C9—Dexamethasone—psoriasis	0.0118	0.0153	CbGbCtD
Tranylcypromine—CYP3A4—Betamethasone—psoriasis	0.0118	0.0153	CbGbCtD
Tranylcypromine—CYP3A4—Prednisolone—psoriasis	0.0116	0.0151	CbGbCtD
Tranylcypromine—CYP3A4—Hydrocortisone—psoriasis	0.011	0.0143	CbGbCtD
Tranylcypromine—CYP3A4—Prednisone—psoriasis	0.011	0.0143	CbGbCtD
Tranylcypromine—CYP2D6—Dexamethasone—psoriasis	0.0108	0.014	CbGbCtD
Tranylcypromine—CYP3A4—Cyclosporine—psoriasis	0.0104	0.0135	CbGbCtD
Tranylcypromine—CYP3A4—Dexamethasone—psoriasis	0.00685	0.00891	CbGbCtD
Tranylcypromine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00342	0.066	CbGpPWpGaD
Tranylcypromine—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00271	0.0521	CbGpPWpGaD
Tranylcypromine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00212	0.0409	CbGpPWpGaD
Tranylcypromine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00209	0.0402	CbGpPWpGaD
Tranylcypromine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00192	0.037	CbGpPWpGaD
Tranylcypromine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.0019	0.0367	CbGpPWpGaD
Tranylcypromine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00179	0.0345	CbGpPWpGaD
Tranylcypromine—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00168	0.0323	CbGpPWpGaD
Tranylcypromine—MAOB—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00147	0.0283	CbGpPWpGaD
Tranylcypromine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00129	0.0249	CbGpPWpGaD
Tranylcypromine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.00119	0.0229	CbGpPWpGaD
Tranylcypromine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00118	0.0227	CbGpPWpGaD
Tranylcypromine—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.00101	0.0194	CbGpPWpGaD
Tranylcypromine—MAOA—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00092	0.0177	CbGpPWpGaD
Tranylcypromine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000881	0.017	CbGpPWpGaD
Tranylcypromine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00087	0.0168	CbGpPWpGaD
Tranylcypromine—MAOB—Biological oxidations—CYP2S1—psoriasis	0.000779	0.015	CbGpPWpGaD
Tranylcypromine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000778	0.015	CbGpPWpGaD
Tranylcypromine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000714	0.0138	CbGpPWpGaD
Tranylcypromine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000696	0.0134	CbGpPWpGaD
Tranylcypromine—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000687	0.0132	CbGpPWpGaD
Tranylcypromine—MAOB—Tryptophan metabolism—CAT—psoriasis	0.000672	0.013	CbGpPWpGaD
Tranylcypromine—MAOA—Oxidative Stress—CAT—psoriasis	0.000594	0.0114	CbGpPWpGaD
Tranylcypromine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000564	0.0109	CbGpPWpGaD
Tranylcypromine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000552	0.0106	CbGpPWpGaD
Tranylcypromine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000537	0.0104	CbGpPWpGaD
Tranylcypromine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00053	0.0102	CbGpPWpGaD
Tranylcypromine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000494	0.00952	CbGpPWpGaD
Tranylcypromine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00049	0.00944	CbGpPWpGaD
Tranylcypromine—MAOA—Biological oxidations—CYP2S1—psoriasis	0.000489	0.00942	CbGpPWpGaD
Tranylcypromine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000488	0.0094	CbGpPWpGaD
Tranylcypromine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000483	0.00932	CbGpPWpGaD
Tranylcypromine—MAOA—Melatonin metabolism and effects—APOE—psoriasis	0.000474	0.00913	CbGpPWpGaD
Tranylcypromine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000436	0.00839	CbGpPWpGaD
Tranylcypromine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000419	0.00807	CbGpPWpGaD
Tranylcypromine—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000413	0.00796	CbGpPWpGaD
Tranylcypromine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000401	0.00772	CbGpPWpGaD
Tranylcypromine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000397	0.00765	CbGpPWpGaD
Tranylcypromine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000379	0.00731	CbGpPWpGaD
Tranylcypromine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000366	0.00705	CbGpPWpGaD
Tranylcypromine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000352	0.00679	CbGpPWpGaD
Tranylcypromine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000339	0.00654	CbGpPWpGaD
Tranylcypromine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000323	0.00623	CbGpPWpGaD
Tranylcypromine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00032	0.00616	CbGpPWpGaD
Tranylcypromine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.00032	0.00616	CbGpPWpGaD
Tranylcypromine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000319	0.00615	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000304	0.00585	CbGpPWpGaD
Tranylcypromine—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.0003	0.00578	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000296	0.0057	CbGpPWpGaD
Tranylcypromine—MAOA—Melatonin metabolism and effects—NFKB1—psoriasis	0.000282	0.00543	CbGpPWpGaD
Tranylcypromine—MAOA—Oxidative Stress—NFKB1—psoriasis	0.000274	0.00529	CbGpPWpGaD
Tranylcypromine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000262	0.00505	CbGpPWpGaD
Tranylcypromine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000259	0.00499	CbGpPWpGaD
Tranylcypromine—Oedema—Mycophenolate mofetil—psoriasis	0.000259	0.00144	CcSEcCtD
Tranylcypromine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000258	0.00498	CbGpPWpGaD
Tranylcypromine—Hyperhidrosis—Cyclosporine—psoriasis	0.000256	0.00143	CcSEcCtD
Tranylcypromine—Hypertension—Prednisolone—psoriasis	0.000255	0.00142	CcSEcCtD
Tranylcypromine—Shock—Mycophenolate mofetil—psoriasis	0.000255	0.00141	CcSEcCtD
Tranylcypromine—Loss of consciousness—Hydrocortisone—psoriasis	0.000254	0.00141	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000253	0.00141	CcSEcCtD
Tranylcypromine—Anorexia—Cyclosporine—psoriasis	0.000253	0.00141	CcSEcCtD
Tranylcypromine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000252	0.0014	CcSEcCtD
Tranylcypromine—Bradycardia—Prednisone—psoriasis	0.000251	0.0014	CcSEcCtD
Tranylcypromine—Alopecia—Dexamethasone—psoriasis	0.00025	0.00139	CcSEcCtD
Tranylcypromine—Alopecia—Betamethasone—psoriasis	0.00025	0.00139	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00025	0.00139	CcSEcCtD
Tranylcypromine—Hypertension—Hydrocortisone—psoriasis	0.000249	0.00139	CcSEcCtD
Tranylcypromine—Vomiting—Hydroxyurea—psoriasis	0.000249	0.00138	CcSEcCtD
Tranylcypromine—Haemoglobin—Prednisone—psoriasis	0.000248	0.00138	CcSEcCtD
Tranylcypromine—Haemorrhage—Prednisone—psoriasis	0.000247	0.00137	CcSEcCtD
Tranylcypromine—Rash—Hydroxyurea—psoriasis	0.000247	0.00137	CcSEcCtD
Tranylcypromine—Anorexia—Mycophenolate mofetil—psoriasis	0.000247	0.00137	CcSEcCtD
Tranylcypromine—Dermatitis—Hydroxyurea—psoriasis	0.000247	0.00137	CcSEcCtD
Tranylcypromine—Headache—Hydroxyurea—psoriasis	0.000245	0.00136	CcSEcCtD
Tranylcypromine—Anxiety—Hydrocortisone—psoriasis	0.000245	0.00136	CcSEcCtD
Tranylcypromine—Syncope—Triamcinolone—psoriasis	0.000244	0.00136	CcSEcCtD
Tranylcypromine—Hypotension—Mycophenolate mofetil—psoriasis	0.000242	0.00134	CcSEcCtD
Tranylcypromine—Oedema—Prednisolone—psoriasis	0.000241	0.00134	CcSEcCtD
Tranylcypromine—Insomnia—Cyclosporine—psoriasis	0.00024	0.00133	CcSEcCtD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL13—psoriasis	0.00024	0.00462	CbGpPWpGaD
Tranylcypromine—Loss of consciousness—Triamcinolone—psoriasis	0.000239	0.00133	CcSEcCtD
Tranylcypromine—Paraesthesia—Cyclosporine—psoriasis	0.000238	0.00132	CcSEcCtD
Tranylcypromine—Shock—Prednisolone—psoriasis	0.000237	0.00132	CcSEcCtD
Tranylcypromine—Erectile dysfunction—Methotrexate—psoriasis	0.000237	0.00132	CcSEcCtD
Tranylcypromine—Somnolence—Cyclosporine—psoriasis	0.000236	0.00131	CcSEcCtD
Tranylcypromine—Oedema—Hydrocortisone—psoriasis	0.000236	0.00131	CcSEcCtD
Tranylcypromine—Tachycardia—Prednisolone—psoriasis	0.000236	0.00131	CcSEcCtD
Tranylcypromine—Asthenia—Mycophenolic acid—psoriasis	0.000235	0.00131	CcSEcCtD
Tranylcypromine—Hypertension—Triamcinolone—psoriasis	0.000235	0.00131	CcSEcCtD
Tranylcypromine—Insomnia—Mycophenolate mofetil—psoriasis	0.000234	0.0013	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Prednisolone—psoriasis	0.000233	0.0013	CcSEcCtD
Tranylcypromine—Nausea—Hydroxyurea—psoriasis	0.000232	0.00129	CcSEcCtD
Tranylcypromine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000232	0.00129	CcSEcCtD
Tranylcypromine—Shock—Hydrocortisone—psoriasis	0.000232	0.00129	CcSEcCtD
Tranylcypromine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000231	0.00446	CbGpPWpGaD
Tranylcypromine—Decreased appetite—Cyclosporine—psoriasis	0.000231	0.00128	CcSEcCtD
Tranylcypromine—Tachycardia—Hydrocortisone—psoriasis	0.00023	0.00128	CcSEcCtD
Tranylcypromine—Somnolence—Mycophenolate mofetil—psoriasis	0.00023	0.00128	CcSEcCtD
Tranylcypromine—Drowsiness—Methotrexate—psoriasis	0.00023	0.00128	CcSEcCtD
Tranylcypromine—Flushing—Prednisone—psoriasis	0.000229	0.00127	CcSEcCtD
Tranylcypromine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000228	0.0044	CbGpPWpGaD
Tranylcypromine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000228	0.00127	CcSEcCtD
Tranylcypromine—Pain—Cyclosporine—psoriasis	0.000227	0.00126	CcSEcCtD
Tranylcypromine—Constipation—Cyclosporine—psoriasis	0.000227	0.00126	CcSEcCtD
Tranylcypromine—Dry mouth—Triamcinolone—psoriasis	0.000226	0.00126	CcSEcCtD
Tranylcypromine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000225	0.00434	CbGpPWpGaD
Tranylcypromine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000225	0.00125	CcSEcCtD
Tranylcypromine—Anorexia—Hydrocortisone—psoriasis	0.000225	0.00125	CcSEcCtD
Tranylcypromine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000224	0.00432	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Mycophenolic acid—psoriasis	0.000224	0.00125	CcSEcCtD
Tranylcypromine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000223	0.0043	CbGpPWpGaD
Tranylcypromine—Oedema—Triamcinolone—psoriasis	0.000222	0.00123	CcSEcCtD
Tranylcypromine—Syncope—Betamethasone—psoriasis	0.000221	0.00123	CcSEcCtD
Tranylcypromine—Syncope—Dexamethasone—psoriasis	0.000221	0.00123	CcSEcCtD
Tranylcypromine—Constipation—Mycophenolate mofetil—psoriasis	0.000221	0.00123	CcSEcCtD
Tranylcypromine—Pain—Mycophenolate mofetil—psoriasis	0.000221	0.00123	CcSEcCtD
Tranylcypromine—Sweating—Methotrexate—psoriasis	0.00022	0.00122	CcSEcCtD
Tranylcypromine—Hypotension—Hydrocortisone—psoriasis	0.00022	0.00122	CcSEcCtD
Tranylcypromine—Feeling abnormal—Cyclosporine—psoriasis	0.000219	0.00121	CcSEcCtD
Tranylcypromine—Shock—Triamcinolone—psoriasis	0.000218	0.00121	CcSEcCtD
Tranylcypromine—Insomnia—Prednisolone—psoriasis	0.000218	0.00121	CcSEcCtD
Tranylcypromine—Alopecia—Prednisone—psoriasis	0.000218	0.00121	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000217	0.00121	CcSEcCtD
Tranylcypromine—Loss of consciousness—Betamethasone—psoriasis	0.000217	0.00121	CcSEcCtD
Tranylcypromine—Loss of consciousness—Dexamethasone—psoriasis	0.000217	0.00121	CcSEcCtD
Tranylcypromine—Dizziness—Mycophenolic acid—psoriasis	0.000217	0.00121	CcSEcCtD
Tranylcypromine—Paraesthesia—Prednisolone—psoriasis	0.000217	0.0012	CcSEcCtD
Tranylcypromine—Tachycardia—Triamcinolone—psoriasis	0.000217	0.0012	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Triamcinolone—psoriasis	0.000215	0.00119	CcSEcCtD
Tranylcypromine—Agranulocytosis—Methotrexate—psoriasis	0.000214	0.00119	CcSEcCtD
Tranylcypromine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000213	0.00119	CcSEcCtD
Tranylcypromine—Insomnia—Hydrocortisone—psoriasis	0.000213	0.00119	CcSEcCtD
Tranylcypromine—Hypertension—Dexamethasone—psoriasis	0.000213	0.00118	CcSEcCtD
Tranylcypromine—Hypertension—Betamethasone—psoriasis	0.000213	0.00118	CcSEcCtD
Tranylcypromine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000213	0.0041	CbGpPWpGaD
Tranylcypromine—Paraesthesia—Hydrocortisone—psoriasis	0.000212	0.00118	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000212	0.00118	CcSEcCtD
Tranylcypromine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000211	0.00407	CbGpPWpGaD
Tranylcypromine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000211	0.00407	CbGpPWpGaD
Tranylcypromine—Urticaria—Cyclosporine—psoriasis	0.000211	0.00117	CcSEcCtD
Tranylcypromine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00021	0.00404	CbGpPWpGaD
Tranylcypromine—Body temperature increased—Cyclosporine—psoriasis	0.00021	0.00117	CcSEcCtD
Tranylcypromine—Abdominal pain—Cyclosporine—psoriasis	0.00021	0.00117	CcSEcCtD
Tranylcypromine—Anxiety—Betamethasone—psoriasis	0.000209	0.00116	CcSEcCtD
Tranylcypromine—Anxiety—Dexamethasone—psoriasis	0.000209	0.00116	CcSEcCtD
Tranylcypromine—Vomiting—Mycophenolic acid—psoriasis	0.000208	0.00116	CcSEcCtD
Tranylcypromine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000208	0.00401	CbGpPWpGaD
Tranylcypromine—Haemoglobin—Methotrexate—psoriasis	0.000207	0.00115	CcSEcCtD
Tranylcypromine—Rash—Mycophenolic acid—psoriasis	0.000207	0.00115	CcSEcCtD
Tranylcypromine—Dermatitis—Mycophenolic acid—psoriasis	0.000206	0.00115	CcSEcCtD
Tranylcypromine—Pain—Prednisolone—psoriasis	0.000206	0.00115	CcSEcCtD
Tranylcypromine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000206	0.00398	CbGpPWpGaD
Tranylcypromine—Haemorrhage—Methotrexate—psoriasis	0.000206	0.00115	CcSEcCtD
Tranylcypromine—Hepatitis—Methotrexate—psoriasis	0.000206	0.00115	CcSEcCtD
Tranylcypromine—Urticaria—Mycophenolate mofetil—psoriasis	0.000206	0.00114	CcSEcCtD
Tranylcypromine—Headache—Mycophenolic acid—psoriasis	0.000205	0.00114	CcSEcCtD
Tranylcypromine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000205	0.00395	CbGpPWpGaD
Tranylcypromine—Decreased appetite—Hydrocortisone—psoriasis	0.000205	0.00114	CcSEcCtD
Tranylcypromine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000204	0.00114	CcSEcCtD
Tranylcypromine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000204	0.00114	CcSEcCtD
Tranylcypromine—Vision blurred—Prednisone—psoriasis	0.000202	0.00113	CcSEcCtD
Tranylcypromine—Pain—Hydrocortisone—psoriasis	0.000202	0.00112	CcSEcCtD
Tranylcypromine—Oedema—Betamethasone—psoriasis	0.000201	0.00112	CcSEcCtD
Tranylcypromine—Oedema—Dexamethasone—psoriasis	0.000201	0.00112	CcSEcCtD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000201	0.00387	CbGpPWpGaD
Tranylcypromine—Insomnia—Triamcinolone—psoriasis	0.000201	0.00112	CcSEcCtD
Tranylcypromine—Paraesthesia—Triamcinolone—psoriasis	0.000199	0.00111	CcSEcCtD
Tranylcypromine—Feeling abnormal—Prednisolone—psoriasis	0.000199	0.00111	CcSEcCtD
Tranylcypromine—Anaemia—Prednisone—psoriasis	0.000199	0.0011	CcSEcCtD
Tranylcypromine—Shock—Betamethasone—psoriasis	0.000198	0.0011	CcSEcCtD
Tranylcypromine—Shock—Dexamethasone—psoriasis	0.000198	0.0011	CcSEcCtD
Tranylcypromine—Agitation—Prednisone—psoriasis	0.000197	0.0011	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Dexamethasone—psoriasis	0.000197	0.0011	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Betamethasone—psoriasis	0.000197	0.0011	CcSEcCtD
Tranylcypromine—Tachycardia—Dexamethasone—psoriasis	0.000197	0.00109	CcSEcCtD
Tranylcypromine—Tachycardia—Betamethasone—psoriasis	0.000197	0.00109	CcSEcCtD
Tranylcypromine—Nausea—Mycophenolic acid—psoriasis	0.000195	0.00108	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Dexamethasone—psoriasis	0.000195	0.00108	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Betamethasone—psoriasis	0.000195	0.00108	CcSEcCtD
Tranylcypromine—Feeling abnormal—Hydrocortisone—psoriasis	0.000194	0.00108	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000193	0.00107	CcSEcCtD
Tranylcypromine—Syncope—Prednisone—psoriasis	0.000193	0.00107	CcSEcCtD
Tranylcypromine—Tinnitus—Methotrexate—psoriasis	0.000192	0.00107	CcSEcCtD
Tranylcypromine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000192	0.00371	CbGpPWpGaD
Tranylcypromine—Anorexia—Dexamethasone—psoriasis	0.000192	0.00107	CcSEcCtD
Tranylcypromine—Anorexia—Betamethasone—psoriasis	0.000192	0.00107	CcSEcCtD
Tranylcypromine—Urticaria—Prednisolone—psoriasis	0.000192	0.00107	CcSEcCtD
Tranylcypromine—Asthenia—Cyclosporine—psoriasis	0.00019	0.00106	CcSEcCtD
Tranylcypromine—Pain—Triamcinolone—psoriasis	0.00019	0.00105	CcSEcCtD
Tranylcypromine—Loss of consciousness—Prednisone—psoriasis	0.000189	0.00105	CcSEcCtD
Tranylcypromine—Hypotension—Betamethasone—psoriasis	0.000188	0.00105	CcSEcCtD
Tranylcypromine—Hypotension—Dexamethasone—psoriasis	0.000188	0.00105	CcSEcCtD
Tranylcypromine—Urticaria—Hydrocortisone—psoriasis	0.000187	0.00104	CcSEcCtD
Tranylcypromine—Abdominal pain—Hydrocortisone—psoriasis	0.000186	0.00104	CcSEcCtD
Tranylcypromine—Body temperature increased—Hydrocortisone—psoriasis	0.000186	0.00104	CcSEcCtD
Tranylcypromine—Asthenia—Mycophenolate mofetil—psoriasis	0.000186	0.00103	CcSEcCtD
Tranylcypromine—Hypertension—Prednisone—psoriasis	0.000185	0.00103	CcSEcCtD
Tranylcypromine—Chills—Methotrexate—psoriasis	0.000185	0.00103	CcSEcCtD
Tranylcypromine—Feeling abnormal—Triamcinolone—psoriasis	0.000183	0.00102	CcSEcCtD
Tranylcypromine—Anxiety—Prednisone—psoriasis	0.000182	0.00101	CcSEcCtD
Tranylcypromine—Alopecia—Methotrexate—psoriasis	0.000182	0.00101	CcSEcCtD
Tranylcypromine—Insomnia—Dexamethasone—psoriasis	0.000182	0.00101	CcSEcCtD
Tranylcypromine—Insomnia—Betamethasone—psoriasis	0.000182	0.00101	CcSEcCtD
Tranylcypromine—Diarrhoea—Cyclosporine—psoriasis	0.000181	0.00101	CcSEcCtD
Tranylcypromine—Paraesthesia—Betamethasone—psoriasis	0.000181	0.00101	CcSEcCtD
Tranylcypromine—Paraesthesia—Dexamethasone—psoriasis	0.000181	0.00101	CcSEcCtD
Tranylcypromine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.00018	0.00347	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000178	0.00343	CbGpPWpGaD
Tranylcypromine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000177	0.00342	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000177	0.000984	CcSEcCtD
Tranylcypromine—Urticaria—Triamcinolone—psoriasis	0.000176	0.00098	CcSEcCtD
Tranylcypromine—Body temperature increased—Triamcinolone—psoriasis	0.000175	0.000975	CcSEcCtD
Tranylcypromine—Dizziness—Cyclosporine—psoriasis	0.000175	0.000975	CcSEcCtD
Tranylcypromine—Oedema—Prednisone—psoriasis	0.000175	0.000975	CcSEcCtD
Tranylcypromine—Decreased appetite—Betamethasone—psoriasis	0.000175	0.000973	CcSEcCtD
Tranylcypromine—Decreased appetite—Dexamethasone—psoriasis	0.000175	0.000973	CcSEcCtD
Tranylcypromine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000175	0.00337	CbGpPWpGaD
Tranylcypromine—Shock—Prednisone—psoriasis	0.000173	0.000959	CcSEcCtD
Tranylcypromine—Pain—Dexamethasone—psoriasis	0.000172	0.000957	CcSEcCtD
Tranylcypromine—Pain—Betamethasone—psoriasis	0.000172	0.000957	CcSEcCtD
Tranylcypromine—Tachycardia—Prednisone—psoriasis	0.000171	0.000951	CcSEcCtD
Tranylcypromine—Dizziness—Mycophenolate mofetil—psoriasis	0.000171	0.000951	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Prednisone—psoriasis	0.00017	0.000942	CcSEcCtD
Tranylcypromine—Vision blurred—Methotrexate—psoriasis	0.000169	0.000941	CcSEcCtD
Tranylcypromine—Asthenia—Hydrocortisone—psoriasis	0.000169	0.00094	CcSEcCtD
Tranylcypromine—Vomiting—Cyclosporine—psoriasis	0.000169	0.000937	CcSEcCtD
Tranylcypromine—Rash—Cyclosporine—psoriasis	0.000167	0.00093	CcSEcCtD
Tranylcypromine—Anorexia—Prednisone—psoriasis	0.000167	0.000929	CcSEcCtD
Tranylcypromine—Dermatitis—Cyclosporine—psoriasis	0.000167	0.000929	CcSEcCtD
Tranylcypromine—Headache—Cyclosporine—psoriasis	0.000166	0.000924	CcSEcCtD
Tranylcypromine—Anaemia—Methotrexate—psoriasis	0.000166	0.000923	CcSEcCtD
Tranylcypromine—Feeling abnormal—Dexamethasone—psoriasis	0.000166	0.000922	CcSEcCtD
Tranylcypromine—Feeling abnormal—Betamethasone—psoriasis	0.000166	0.000922	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000165	0.000915	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Betamethasone—psoriasis	0.000165	0.000915	CcSEcCtD
Tranylcypromine—Vomiting—Mycophenolate mofetil—psoriasis	0.000164	0.000914	CcSEcCtD
Tranylcypromine—Rash—Mycophenolate mofetil—psoriasis	0.000163	0.000907	CcSEcCtD
Tranylcypromine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000163	0.000906	CcSEcCtD
Tranylcypromine—Headache—Mycophenolate mofetil—psoriasis	0.000162	0.000901	CcSEcCtD
Tranylcypromine—Diarrhoea—Hydrocortisone—psoriasis	0.000161	0.000896	CcSEcCtD
Tranylcypromine—Leukopenia—Methotrexate—psoriasis	0.000161	0.000894	CcSEcCtD
Tranylcypromine—Urticaria—Dexamethasone—psoriasis	0.00016	0.000889	CcSEcCtD
Tranylcypromine—Urticaria—Betamethasone—psoriasis	0.00016	0.000889	CcSEcCtD
Tranylcypromine—Dizziness—Prednisolone—psoriasis	0.00016	0.000887	CcSEcCtD
Tranylcypromine—Asthenia—Triamcinolone—psoriasis	0.000159	0.000885	CcSEcCtD
Tranylcypromine—Abdominal pain—Betamethasone—psoriasis	0.000159	0.000885	CcSEcCtD
Tranylcypromine—Body temperature increased—Betamethasone—psoriasis	0.000159	0.000885	CcSEcCtD
Tranylcypromine—Abdominal pain—Dexamethasone—psoriasis	0.000159	0.000885	CcSEcCtD
Tranylcypromine—Body temperature increased—Dexamethasone—psoriasis	0.000159	0.000885	CcSEcCtD
Tranylcypromine—Insomnia—Prednisone—psoriasis	0.000159	0.000882	CcSEcCtD
Tranylcypromine—Nausea—Cyclosporine—psoriasis	0.000158	0.000876	CcSEcCtD
Tranylcypromine—Paraesthesia—Prednisone—psoriasis	0.000157	0.000875	CcSEcCtD
Tranylcypromine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000157	0.00302	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—NDUFA5—psoriasis	0.000157	0.00302	CbGpPWpGaD
Tranylcypromine—Dizziness—Hydrocortisone—psoriasis	0.000156	0.000866	CcSEcCtD
Tranylcypromine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000156	0.003	CbGpPWpGaD
Tranylcypromine—Nausea—Mycophenolate mofetil—psoriasis	0.000154	0.000854	CcSEcCtD
Tranylcypromine—Decreased appetite—Prednisone—psoriasis	0.000152	0.000847	CcSEcCtD
Tranylcypromine—Rash—Prednisolone—psoriasis	0.000152	0.000846	CcSEcCtD
Tranylcypromine—Dermatitis—Prednisolone—psoriasis	0.000152	0.000845	CcSEcCtD
Tranylcypromine—Headache—Prednisolone—psoriasis	0.000151	0.00084	CcSEcCtD
Tranylcypromine—Constipation—Prednisone—psoriasis	0.00015	0.000834	CcSEcCtD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL10—psoriasis	0.00015	0.00289	CbGpPWpGaD
Tranylcypromine—Vomiting—Hydrocortisone—psoriasis	0.00015	0.000833	CcSEcCtD
Tranylcypromine—Rash—Hydrocortisone—psoriasis	0.000149	0.000826	CcSEcCtD
Tranylcypromine—Dermatitis—Hydrocortisone—psoriasis	0.000148	0.000825	CcSEcCtD
Tranylcypromine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000148	0.00286	CbGpPWpGaD
Tranylcypromine—Confusional state—Methotrexate—psoriasis	0.000148	0.000821	CcSEcCtD
Tranylcypromine—Headache—Hydrocortisone—psoriasis	0.000148	0.000821	CcSEcCtD
Tranylcypromine—Dizziness—Triamcinolone—psoriasis	0.000147	0.000816	CcSEcCtD
Tranylcypromine—Feeling abnormal—Prednisone—psoriasis	0.000144	0.000803	CcSEcCtD
Tranylcypromine—Asthenia—Betamethasone—psoriasis	0.000144	0.000803	CcSEcCtD
Tranylcypromine—Asthenia—Dexamethasone—psoriasis	0.000144	0.000803	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Methotrexate—psoriasis	0.000143	0.000798	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Prednisone—psoriasis	0.000143	0.000797	CcSEcCtD
Tranylcypromine—Nausea—Prednisolone—psoriasis	0.000143	0.000797	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Methotrexate—psoriasis	0.000142	0.000788	CcSEcCtD
Tranylcypromine—Vomiting—Triamcinolone—psoriasis	0.000141	0.000784	CcSEcCtD
Tranylcypromine—Nausea—Hydrocortisone—psoriasis	0.00014	0.000778	CcSEcCtD
Tranylcypromine—Rash—Triamcinolone—psoriasis	0.00014	0.000778	CcSEcCtD
Tranylcypromine—Dermatitis—Triamcinolone—psoriasis	0.00014	0.000777	CcSEcCtD
Tranylcypromine—Anorexia—Methotrexate—psoriasis	0.00014	0.000777	CcSEcCtD
Tranylcypromine—Urticaria—Prednisone—psoriasis	0.000139	0.000774	CcSEcCtD
Tranylcypromine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000139	0.00268	CbGpPWpGaD
Tranylcypromine—Headache—Triamcinolone—psoriasis	0.000139	0.000773	CcSEcCtD
Tranylcypromine—Abdominal pain—Prednisone—psoriasis	0.000139	0.000771	CcSEcCtD
Tranylcypromine—Body temperature increased—Prednisone—psoriasis	0.000139	0.000771	CcSEcCtD
Tranylcypromine—Diarrhoea—Betamethasone—psoriasis	0.000138	0.000766	CcSEcCtD
Tranylcypromine—Diarrhoea—Dexamethasone—psoriasis	0.000138	0.000766	CcSEcCtD
Tranylcypromine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000137	0.00264	CbGpPWpGaD
Tranylcypromine—Hypotension—Methotrexate—psoriasis	0.000137	0.000761	CcSEcCtD
Tranylcypromine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000135	0.00261	CbGpPWpGaD
Tranylcypromine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000134	0.00258	CbGpPWpGaD
Tranylcypromine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000133	0.00257	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—CYP2S1—psoriasis	0.000133	0.00257	CbGpPWpGaD
Tranylcypromine—Dizziness—Dexamethasone—psoriasis	0.000133	0.00074	CcSEcCtD
Tranylcypromine—Dizziness—Betamethasone—psoriasis	0.000133	0.00074	CcSEcCtD
Tranylcypromine—Insomnia—Methotrexate—psoriasis	0.000133	0.000737	CcSEcCtD
Tranylcypromine—Nausea—Triamcinolone—psoriasis	0.000132	0.000733	CcSEcCtD
Tranylcypromine—Paraesthesia—Methotrexate—psoriasis	0.000132	0.000732	CcSEcCtD
Tranylcypromine—Somnolence—Methotrexate—psoriasis	0.00013	0.000724	CcSEcCtD
Tranylcypromine—Vomiting—Dexamethasone—psoriasis	0.000128	0.000712	CcSEcCtD
Tranylcypromine—Vomiting—Betamethasone—psoriasis	0.000128	0.000712	CcSEcCtD
Tranylcypromine—Decreased appetite—Methotrexate—psoriasis	0.000127	0.000708	CcSEcCtD
Tranylcypromine—Rash—Dexamethasone—psoriasis	0.000127	0.000706	CcSEcCtD
Tranylcypromine—Rash—Betamethasone—psoriasis	0.000127	0.000706	CcSEcCtD
Tranylcypromine—Dermatitis—Betamethasone—psoriasis	0.000127	0.000705	CcSEcCtD
Tranylcypromine—Dermatitis—Dexamethasone—psoriasis	0.000127	0.000705	CcSEcCtD
Tranylcypromine—Headache—Betamethasone—psoriasis	0.000126	0.000701	CcSEcCtD
Tranylcypromine—Headache—Dexamethasone—psoriasis	0.000126	0.000701	CcSEcCtD
Tranylcypromine—Asthenia—Prednisone—psoriasis	0.000126	0.000699	CcSEcCtD
Tranylcypromine—Pain—Methotrexate—psoriasis	0.000125	0.000697	CcSEcCtD
Tranylcypromine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000123	0.00236	CbGpPWpGaD
Tranylcypromine—Feeling abnormal—Methotrexate—psoriasis	0.000121	0.000671	CcSEcCtD
Tranylcypromine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.00012	0.00231	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Prednisone—psoriasis	0.00012	0.000667	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Methotrexate—psoriasis	0.00012	0.000666	CcSEcCtD
Tranylcypromine—Nausea—Betamethasone—psoriasis	0.00012	0.000665	CcSEcCtD
Tranylcypromine—Nausea—Dexamethasone—psoriasis	0.00012	0.000665	CcSEcCtD
Tranylcypromine—Urticaria—Methotrexate—psoriasis	0.000116	0.000647	CcSEcCtD
Tranylcypromine—Dizziness—Prednisone—psoriasis	0.000116	0.000645	CcSEcCtD
Tranylcypromine—Abdominal pain—Methotrexate—psoriasis	0.000116	0.000644	CcSEcCtD
Tranylcypromine—Body temperature increased—Methotrexate—psoriasis	0.000116	0.000644	CcSEcCtD
Tranylcypromine—Vomiting—Prednisone—psoriasis	0.000111	0.00062	CcSEcCtD
Tranylcypromine—Rash—Prednisone—psoriasis	0.000111	0.000615	CcSEcCtD
Tranylcypromine—Dermatitis—Prednisone—psoriasis	0.00011	0.000614	CcSEcCtD
Tranylcypromine—Headache—Prednisone—psoriasis	0.00011	0.000611	CcSEcCtD
Tranylcypromine—Asthenia—Methotrexate—psoriasis	0.000105	0.000585	CcSEcCtD
Tranylcypromine—Nausea—Prednisone—psoriasis	0.000104	0.000579	CcSEcCtD
Tranylcypromine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.002	CbGpPWpGaD
Tranylcypromine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000103	0.00199	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Methotrexate—psoriasis	0.0001	0.000557	CcSEcCtD
Tranylcypromine—MAOA—Metabolism—NDUFA5—psoriasis	9.83e-05	0.00189	CbGpPWpGaD
Tranylcypromine—Dizziness—Methotrexate—psoriasis	9.69e-05	0.000539	CcSEcCtD
Tranylcypromine—Vomiting—Methotrexate—psoriasis	9.32e-05	0.000518	CcSEcCtD
Tranylcypromine—Rash—Methotrexate—psoriasis	9.24e-05	0.000514	CcSEcCtD
Tranylcypromine—Dermatitis—Methotrexate—psoriasis	9.23e-05	0.000513	CcSEcCtD
Tranylcypromine—Headache—Methotrexate—psoriasis	9.18e-05	0.00051	CcSEcCtD
Tranylcypromine—Nausea—Methotrexate—psoriasis	8.7e-05	0.000484	CcSEcCtD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	8.64e-05	0.00166	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—CYP2S1—psoriasis	8.36e-05	0.00161	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.2e-05	0.00158	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—NDUFA5—psoriasis	7.63e-05	0.00147	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—JUN—psoriasis	7.62e-05	0.00147	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.47e-05	0.00144	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.33e-05	0.00141	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.19e-05	0.00139	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.66e-05	0.00128	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.52e-05	0.00126	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—CARM1—psoriasis	6.51e-05	0.00125	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—CYP2S1—psoriasis	6.49e-05	0.00125	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—NDUFA5—psoriasis	6.03e-05	0.00116	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—TNF—psoriasis	5.71e-05	0.0011	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.59e-05	0.00108	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.59e-05	0.00108	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—CYP2S1—psoriasis	5.13e-05	0.000988	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—NDUFA5—psoriasis	4.65e-05	0.000897	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL6—psoriasis	4.6e-05	0.000887	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.34e-05	0.000836	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—NDUFA5—psoriasis	4.28e-05	0.000825	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—NDUFA5—psoriasis	4.24e-05	0.000818	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—CARM1—psoriasis	4.08e-05	0.000787	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—CAT—psoriasis	4e-05	0.000771	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—CYP2S1—psoriasis	3.96e-05	0.000763	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.96e-05	0.000762	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—CYP2S1—psoriasis	3.64e-05	0.000701	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—NDUFA5—psoriasis	3.63e-05	0.000699	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—CYP2S1—psoriasis	3.61e-05	0.000695	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.38e-05	0.000652	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—CARM1—psoriasis	3.17e-05	0.000611	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—APOE—psoriasis	3.11e-05	0.000599	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—CYP2S1—psoriasis	3.08e-05	0.000594	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—NDUFA5—psoriasis	2.8e-05	0.000539	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—PPARG—psoriasis	2.71e-05	0.000522	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—CAT—psoriasis	2.51e-05	0.000484	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—CARM1—psoriasis	2.5e-05	0.000483	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—CYP2S1—psoriasis	2.38e-05	0.000459	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.07e-05	0.0004	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—APOE—psoriasis	1.95e-05	0.000376	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—CAT—psoriasis	1.95e-05	0.000376	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—CARM1—psoriasis	1.93e-05	0.000372	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.89e-05	0.000364	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.81e-05	0.000348	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—CARM1—psoriasis	1.78e-05	0.000343	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—CARM1—psoriasis	1.76e-05	0.00034	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—PPARG—psoriasis	1.7e-05	0.000328	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.65e-05	0.000317	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.62e-05	0.000311	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—CAT—psoriasis	1.54e-05	0.000297	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—APOE—psoriasis	1.51e-05	0.000292	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—CARM1—psoriasis	1.51e-05	0.00029	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.41e-05	0.000271	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—PPARG—psoriasis	1.32e-05	0.000254	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—APOE—psoriasis	1.2e-05	0.000231	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—CAT—psoriasis	1.19e-05	0.000229	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—CARM1—psoriasis	1.16e-05	0.000224	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—CAT—psoriasis	1.09e-05	0.000211	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—CAT—psoriasis	1.08e-05	0.000209	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—PPARG—psoriasis	1.04e-05	0.000201	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—CAT—psoriasis	9.26e-06	0.000178	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—APOE—psoriasis	9.23e-06	0.000178	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—APOE—psoriasis	8.49e-06	0.000164	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—APOE—psoriasis	8.42e-06	0.000162	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—PPARG—psoriasis	8.04e-06	0.000155	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—PPARG—psoriasis	7.4e-06	0.000143	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—PPARG—psoriasis	7.33e-06	0.000141	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—APOE—psoriasis	7.19e-06	0.000139	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—CAT—psoriasis	7.15e-06	0.000138	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—PPARG—psoriasis	6.27e-06	0.000121	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—APOE—psoriasis	5.55e-06	0.000107	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—PPARG—psoriasis	4.84e-06	9.32e-05	CbGpPWpGaD
